Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma

References

• Kraus M, Alimzhanov MB, Rajewsky N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787–800.
   PubMed Web of Science ®Google Scholar
• Hikida M, Johmura S, Hashimoto A, et al. Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development. J Exp Med 2003;198:581–589.
   PubMed Web of Science ®Google Scholar
• Fuentes-Panana EM, Bannish G, Monroe JG. Basal B-cell receptor signaling in B lymphocytes: mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol Rev 2004;197:26–40.
   PubMed Web of Science ®Google Scholar
• Bogusz AM, Baxter RH, Currie T, et al. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma. Clin Cancer Res 2012; 18:6122–6135.
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013;12: 229–243.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230–2237.
   PubMed Web of Science ®Google Scholar
• Takata M, Sabe H, Hata A, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2 + mobilization through distinct pathways. EMBO J 1994;13:1341–1349.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Maeda A, Ishiai M, et al. Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev 2000;176:19–29.
   PubMed Web of Science ®Google Scholar
• Marshall AJ, Niiro H, Yun TJ, et al. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000;176:30–46.
   PubMed Web of Science ®Google Scholar
• Tan JE, Wong SC, Gan SK, et al. The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes. J Biol Chem 2001;276:20055–20063.
   PubMed Web of Science ®Google Scholar
• Pavan A, Spina M, Canzonieri V, et al. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008;49:2048–2058.
   PubMed Web of Science ®Google Scholar
• Ying H, Li Z, Yang L, et al. Syk mediates BCR- and CD40-signaling integration during B cell activation. Immunobiology 2011;216:566–570.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu H, Coughlin J, et al. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 2005;105:3648–3654.
   PubMedGoogle Scholar
• Gold MR, Scheid MP, Santos L, et al. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J Immunol 1999;163:1894–1905.
   PubMed Web of Science ®Google Scholar
• Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol 1996;156: 4543–4554.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013;161:43–56.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21:723–737.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741–1746.
   PubMed Web of Science ®Google Scholar
• Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22:1755–1766.
   PubMed Web of Science ®Google Scholar
• Cheng S, Coffey G, Zhang XH, et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011; 118:6342–6352.
   PubMed Web of Science ®Google Scholar
• Pozzobon M, Marafioti T, Hansmann ML, et al. Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. Br J Haematol 2004;124:519–533.
   PubMed Web of Science ®Google Scholar
• Marafioti T, Pozzobon M, Hansmann ML, et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004;103:188–193.
   PubMed Web of Science ®Google Scholar
• Marafioti T, Pozzobon M, Hansmann ML, et al. Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia 2005;19:856–861.
   PubMed Web of Science ®Google Scholar
• Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 2002;20:4413–4419.
   PubMed Web of Science ®Google Scholar
• Huynh MQ, Wacker HH, Wundisch T, et al. Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas. Leuk Lymphoma 2008;49:974–983.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070–7078.
   PubMed Web of Science ®Google Scholar
• Chen J, Williams IR, Lee BH, et al. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood 2005;106:328–337.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Koivula S, Nyman H, et al. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod Pathol 2010;23:686–693.
   PubMed Web of Science ®Google Scholar